153 related articles for article (PubMed ID: 32947841)
1. Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases.
Tétu P; Sirven-Villaros L; Cuzzubbo S; Ursu R; Baroudjian B; Delyon J; Nataf F; De Margerie-Mellon C; Allayous C; Lefevre W; Carpentier AF; Lebbé C
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32947841
[TBL] [Abstract][Full Text] [Related]
2. Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma.
Geukes Foppen MH; Brandsma D; Blank CU; van Thienen JV; Haanen JB; Boogerd W
Ann Oncol; 2016 Jun; 27(6):1138-1142. PubMed ID: 26961150
[TBL] [Abstract][Full Text] [Related]
3. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
Bander ED; Yuan M; Carnevale JA; Reiner AS; Panageas KS; Postow MA; Tabar V; Moss NS
Cancer; 2021 Jun; 127(12):2062-2073. PubMed ID: 33651913
[TBL] [Abstract][Full Text] [Related]
4. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
5. High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy.
Dercle L; Ammari S; Roblin E; Bigorgne A; Champiat S; Taihi L; Plaian A; Hans S; Lakiss S; Tselikas L; Rouanne M; Deutsch E; Schwartz LH; Gönen M; Flynn J; Massard C; Soria JC; Robert C; Marabelle A
Eur J Cancer; 2022 Dec; 177():80-93. PubMed ID: 36332438
[TBL] [Abstract][Full Text] [Related]
6. Intracranial Treatment in Melanoma Patients with Brain Metastasis Is Associated with Improved Survival in the Era of Immunotherapy and Anti-BRAF Therapy.
Dalmasso C; Pagès C; Chaltiel L; Sibaud V; Moyal E; Chira C; Sol JC; Latorzeff I; Meyer N; Modesto A
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503304
[TBL] [Abstract][Full Text] [Related]
7. Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
Chorti E; Kebir S; Ahmed MS; Keyvani K; Umutlu L; Kanaki T; Zaremba A; Reinboldt-Jockenhoefer F; Knispel S; Gratsias E; Roesch A; Ugurel S; Scheffler B; Schadendorf D; Livingstone E; Meier F; Glas M; Zimmer L
Eur J Cancer; 2021 May; 148():395-404. PubMed ID: 33789203
[TBL] [Abstract][Full Text] [Related]
8. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).
Ferguson SD; Bindal S; Bassett RL; Haydu LE; McCutcheon IE; Heimberger AB; Li J; O'Brien BJ; Guha-Thakurta N; Tetzlaff MT; Tawbi H; Davies MA; Glitza IC
J Neurooncol; 2019 May; 142(3):499-509. PubMed ID: 30847840
[TBL] [Abstract][Full Text] [Related]
9. Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort.
Tétu P; Allayous C; Oriano B; Dalle S; Mortier L; Leccia MT; Guillot B; Dalac S; Dutriaux C; Lacour JP; Saiag P; Brunet-Possenti F; De Quatrebarbes J; Stoebner PE; Legoupil D; Beylot-Barry M; Lesimple T; Aubin F; Dreno B; Mohamed S; Ballon A; Porcher R; Lebbe C
Eur J Cancer; 2019 May; 112():38-46. PubMed ID: 30909072
[TBL] [Abstract][Full Text] [Related]
10. Leptomeningeal metastases due to melanoma.
Chamberlain M; Kormanik P
Int J Oncol; 1996 Sep; 9(3):505-10. PubMed ID: 21541542
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features and prognostic factors in patients with leptomeningeal metastases].
Li N; Yang BY; Li JL; Zhu JQ; Zou BH; Wang YF; Yu L; Yao XY
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):867-70. PubMed ID: 24447488
[TBL] [Abstract][Full Text] [Related]
12. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.
Rauschenberg R; Bruns J; Brütting J; Daubner D; Lohaus F; Zimmer L; Forschner A; Zips D; Hassel JC; Berking C; Kaehler KC; Utikal J; Gutzmer R; Terheyden P; Meiss F; Rafei-Shamsabadi D; Kiecker F; Debus D; Dabrowski E; Arnold A; Garzarolli M; Kuske M; Beissert S; Löck S; Linn J; Troost EGC; Meier F
Eur J Cancer; 2019 Mar; 110():11-20. PubMed ID: 30739835
[TBL] [Abstract][Full Text] [Related]
13. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study.
Pan Z; Yang G; He H; Zhao G; Yuan T; Li Y; Shi W; Gao P; Dong L; Li Y
Int J Cancer; 2016 Oct; 139(8):1864-72. PubMed ID: 27243238
[TBL] [Abstract][Full Text] [Related]
14. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies.
Choong ES; Lo S; Drummond M; Fogarty GB; Menzies AM; Guminski A; Shivalingam B; Clarke K; Long GV; Hong AM
Eur J Cancer; 2017 Apr; 75():169-178. PubMed ID: 28236768
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis.
Harstad L; Hess KR; Groves MD
Neuro Oncol; 2008 Dec; 10(6):1010-8. PubMed ID: 18708343
[TBL] [Abstract][Full Text] [Related]
16. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
[TBL] [Abstract][Full Text] [Related]
17. Leptomeningeal metastases in high-grade adult glioma: development, diagnosis, management, and outcomes in a series of 34 patients.
Dardis C; Milton K; Ashby L; Shapiro W
Front Neurol; 2014; 5():220. PubMed ID: 25404928
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Treatment for Melanoma Brain Metastases.
Janavicius M; Lachej N; Anglickiene G; Vincerzevskiene I; Brasiuniene B
J Skin Cancer; 2020; 2020():7520924. PubMed ID: 33282420
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis.
Oechsle K; Lange-Brock V; Kruell A; Bokemeyer C; de Wit M
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1729-35. PubMed ID: 20204406
[TBL] [Abstract][Full Text] [Related]
20. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
